138 related articles for article (PubMed ID: 26039609)
21. [Premature ovarian failure after chemotherapy for breast cancer].
Mathelin C; Brettes JP; Diemunsch P
Bull Cancer; 2008 Apr; 95(4):403-12. PubMed ID: 18495569
[TBL] [Abstract][Full Text] [Related]
22. GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma.
Blumenfeld Z; Dann E
J Clin Oncol; 2013 Oct; 31(29):3721. PubMed ID: 24002509
[No Abstract] [Full Text] [Related]
23. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy?
Partridge AH
J Clin Oncol; 2012 Feb; 30(5):479-81. PubMed ID: 22231046
[No Abstract] [Full Text] [Related]
24. Use of hormonal protection for chemotherapy-induced gonadotoxicity.
Kim SS; Lee JR; Jee BC; Suh CS; Kim SH; Ting A; Petroff B
Clin Obstet Gynecol; 2010 Dec; 53(4):740-52. PubMed ID: 21048441
[TBL] [Abstract][Full Text] [Related]
25. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
26. Reply to Z. Blumenfeld et al.
Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2013 Oct; 31(29):3722-3. PubMed ID: 24002513
[No Abstract] [Full Text] [Related]
27. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
Jonat W
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
[TBL] [Abstract][Full Text] [Related]
28. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
29. Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies.
Castelo-Branco C; Rabanal A; Nomdedeu B; Durán M; Arigita M; Balasch J
Fertil Steril; 2009 Oct; 92(4):1260-1263. PubMed ID: 19732883
[TBL] [Abstract][Full Text] [Related]
30. Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer?
Goodwin PJ
J Clin Oncol; 2003 Dec; 21(24):4474-5. PubMed ID: 14610047
[No Abstract] [Full Text] [Related]
31. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
Cheer SM; Plosker GL; Simpson D; Wagstaff AJ
Drugs; 2005; 65(18):2639-55. PubMed ID: 16392882
[TBL] [Abstract][Full Text] [Related]
32. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Pritchard KI
Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
[No Abstract] [Full Text] [Related]
33. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.
Yang B; Shi W; Yang J; Liu H; Zhao H; Li X; Jiao S
Breast; 2013 Apr; 22(2):150-157. PubMed ID: 23298851
[TBL] [Abstract][Full Text] [Related]
34. Endocrine prevention of chemotherapy-induced ovarian failure.
Blumenfeld Z
Future Oncol; 2016 Jul; 12(14):1671-4. PubMed ID: 27250801
[No Abstract] [Full Text] [Related]
35. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
von Minckwitz G; Graf E; Geberth M; Eiermann W; Jonat W; Conrad B; Brunnert K; Gerber B; Vescia S; Wollert J; Kaufmann M
Eur J Cancer; 2006 Aug; 42(12):1780-8. PubMed ID: 16765589
[TBL] [Abstract][Full Text] [Related]
36. Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Blumenfeld Z
J Clin Oncol; 2012 Sep; 30(26):3310; author reply 3312-3. PubMed ID: 22649145
[No Abstract] [Full Text] [Related]
37. GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
Peccatori F; Demeestere I
Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600
[No Abstract] [Full Text] [Related]
38. New hope for young breast cancer patients.
Peres J
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214565
[No Abstract] [Full Text] [Related]
39. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
40. Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.
Ferretti G; Felici A; Carlini P; Cognetti F
J Natl Cancer Inst; 2007 Sep; 99(18):1416. PubMed ID: 17848675
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
